Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 346 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 346 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $30,212.72. Following the completion of the sale, the insider owned 119,346 shares of the company’s stock, valued at $10,421,292.72. This trade represents a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The shares were sold at an average price of $69.84, for a total value of $28,075.68.

Twist Bioscience Stock Up 7.5%

TWST stock opened at $91.35 on Thursday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $93.80. The company has a market capitalization of $5.69 billion, a price-to-earnings ratio of -68.68 and a beta of 2.23. The business’s 50 day moving average price is $65.38 and its two-hundred day moving average price is $50.64. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter in the previous year, the business earned ($0.66) EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, analysts forecast that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stifel Financial Corp increased its holdings in shares of Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after purchasing an additional 305 shares in the last quarter. CWM LLC lifted its holdings in shares of Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after purchasing an additional 407 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after buying an additional 442 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after buying an additional 453 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. TD Cowen upped their target price on shares of Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group assumed coverage on shares of Twist Bioscience in a research note on Monday, June 15th. They set a “buy” rating and a $90.00 price objective on the stock. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a report on Monday, June 15th. Finally, Barclays raised their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $74.60.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.